Michael W. Cripps

Michael W. Cripps

Auto-generated profile, based on publicly available information

Michael W. Cripps

Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in The American Journal of Surgery
Verified
Journal Article
Closed access
TMTarik D. Madni
Tarik D. Madni
DLDavid E. Leshikar
David E. Leshikar
CMChristian T. Minshall
Christian T. Minshall
PNPaul A. Nakonezny
Paul A. Nakonezny
CCCanon C. Cornelius
Canon C. Cornelius
MCMichael W. Cripps
Michael W. Cripps

1 April 2017 in Critical Care Clinics
Verified
Journal Article
Closed access
MSM. Chance Spalding
M. Chance Spalding
MCMichael W. Cripps
Michael W. Cripps
CMChristian T. Minshall
Christian T. Minshall

1 March 1999 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
JMJon T. Mader
Jon T. Mader
MCMichael W. Cripps
Michael W. Cripps
JCJason H. Calhoun
Jason H. Calhoun
Posttraumatic tibial osteomyelitis results from trauma or nosocomial infection from the treatment of trauma that allows organisms to enter bone, proliferate in traumatized tissue, and cause subsequent bone infection. The resulting infection is usually polymicrobial. The patient may be classified using the May and the Cierny-Mader classification systems. The diagnosis is based on the isolation of the pathogen(s) from the bone, or blood cultures. Appropriate therapy of posttraumatic tibial osteomyelitis includes adequate drainage, thorough debridement, obliteration of dead space, stabilization when necessary, wound protection, and specific antimicrobial therapy.

1 January 2019 in The American Journal of Surgery
Verified
Journal Article
Closed access
TMTarik D. Madni
Tarik D. Madni
PNPaul A. Nakonezny
Paul A. Nakonezny
EBEvan Barrios
Evan Barrios
JIJonathan B. Imran
Jonathan B. Imran
ACAudra T. Clark
Audra T. Clark
MCMichael W. Cripps
Michael W. Cripps

1 July 2012 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
MKMatthew E. Kutcher
Matthew E. Kutcher
MCMichael W. Cripps
Michael W. Cripps
RMRyan C. BS McCreery
Ryan C. BS McCreery
ICIan M. Bs Crane
Ian M. Bs Crane
MGMolly D. Bs Greenberg
Molly D. Bs Greenberg
MCMitchell Jay Cohen
Mitchell Jay Cohen
BACKGROUND Recent studies identify a survival benefit from the administration of antifibrinolytic agents in patients with severe injury and trauma. However, identification of hyperfibrinolysis requires thromboelastography, which is not widely available. We hypothesized that analysis of patients with thromboelastography-diagnosed hyperfibrinolysis would identify clinical criteria for empiric antifibrinolytic treatment in the absence of thromboelastography. METHODS From November 2010 to March 2012, serial blood samples were collected from 115 patients with critical injury on arrival to the emergency department of an urban Level I trauma center. Rotational thromboelastography was performed to assess viscoelastic properties of clot formation in the presence and absence of aprotinin to identify treatable hyperfibrinolysis. For 20 patients identified with treatable hyperfibrinolysis, clinical predictors were investigated using receiver operating characteristic analysis. RESULTS Of the 115 patients evaluated, 20% had hyperfibrinolysis, defined as an admission maximal clot lysis of 10% or higher, reversible by aprotinin treatment. Patients with hyperfibrinolysis had significantly lower temperature, pH, and platelet counts and higher international normalized ratio, activated partial thromboplastin time, and D-dimer. Hyperfibrinolysis was associated with multiorgan failure (63.2% vs. 24.6%, p = 0.004) and mortality (52.2% vs. 12.9%, p < 0.001). We then evaluated all non–rotational thromboelastography clinical and laboratory parameters predictive of hyperfibrinolysis using receiver operating characteristic analysis to evaluate potential empiric treatment guidelines. The presence of hypothermia (temperature ≤36.0°C), acidosis (pH ≤7.2), relative coagulopathy (international normalized ratio ≥1.3 or activated partial thromboplastin time ≥30), or relative thrombocytopenia (platelet count ≤200) identified hyperfibrinolysis with 100% sensitivity and 55.4% specificity (area under the curve, 0.777). CONCLUSION Consideration of empiric antifibrinolytic therapy is warranted for patients with critical injury and trauma who present with acidosis, hypothermia, coagulopathy, or relative thrombocytopenia. These clinical predictors identified hyperfibrinolysis with 100% sensitivity while simultaneously eliminating 46.6% of inappropriate therapy compared with the empiric treatment of all injured patients. These criteria will facilitate empiric treatment of hyperfibrinolysis for clinicians without access to thromboelastography. LEVEL OF EVIDENCE Prognostic study, level III.

15 October 2014 in Journal of Neurotrauma
Verified
Journal Article
Open access
RPRachel A. Pastorek
Rachel A. Pastorek
MCMichael W. Cripps
Michael W. Cripps
IBIra H. Bernstein
Ira H. Bernstein
WSWilliam W. Scott
William W. Scott
CMChristopher J. Madden
Christopher J. Madden
HPHerb A. Phelan
Herb A. Phelan
As a basis for venous thromboembolism (VTE) prophylaxis after traumatic brain injury (TBI), we have previously published an algorithm known as the Parkland Protocol. Patients are classified by risk for spontaneous progression of hemorrhage with chemoprophylaxis regimens tailored to each tier. We sought to validate this schema. In our algorithm, patients with any of the following are classified “low risk” for spontaneous progression: subdural hemorrhage ≤8 mm thick; epidural hemorrhage ≤8 mm thick; contusions ≤20 mm in diameter; a single contusion per lobe; any amount of subarachnoid hemorrhage; or any amount of intraventricular hemorrhage. Patients with any injury exceeding these are “moderate risk” for progression, and any patient receiving a monitor or craniotomy is “high risk.” From February 2010 to November 2012, TBI patients were entered into a dedicated database tracking injury types and sizes, risk category at presentation, and progression on subsequent computed tomgraphies (CTs). The cohort ( n =414) was classified as low risk ( n =200), moderate risk ( n =75), or high risk ( n =139) after first CT. After repeat CT scan, radiographic progression was noted in 27% of low-risk, 53% of moderate-risk, and 58% of high-risk subjects. Omnibus analysis of variance test for differences in progression rates was highly significant ( p <0.0001). Tukey's post-hoc test showed the low-risk progression rate to be significantly different than both the moderate- and high-risk arms; no difference was noted between the moderate- and high-risk arms themselves. These criteria are a valid tool for classifying TBI patients into two categories of risk for spontaneous progression. This supports tailored chemoprophylaxis regimens for each arm.